The restricted mean survival time (RMST) analysis technique was introduced in health care research about 25 years ago and since then has become widely used in economics, engineering, business and ...

Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial At a minimum ...

177Lu-DOTATATE Plus Radiosensitizing Capecitabine Versus Octreotide Long-Acting Release as First-Line Systemic Therapy in Advanced Grade 1 or 2 Gastroenteropancreatic Neuroendocrine Tumors: A ...

Five-year follow-up in a trial involving patients with previously untreated stage III or IV classic Hodgkin’s lymphoma showed long-term progression-free survival benefits with first-line therapy with ...

We previously reported that olaparib led to significantly longer imaging-based progression-free survival than the physician’s choice of enzalutamide or abiraterone among men with metastatic castration ...